1 – 3 of 3
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer : A Swedish retrospective cohort study
(
- Contribution to journal › Article
- 2016
-
Mark
Drug utilization research in the area of cancer drugs
2016) p.315-327(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting
(
- Contribution to journal › Article